Difemetorex

Difemetorex
Systematic (IUPAC) name
2-[2-(diphenylmethyl)piperidin-1-yl]ethanol
Clinical data
Legal status
  • Withdrawn
Routes of
administration
Oral
Identifiers
CAS Number 13862-07-2
ATC code None
PubChem CID 65607
ChemSpider 59048
UNII O0417MPF6W YesY
ChEMBL CHEMBL2104291
Chemical data
Formula C20H25NO
Molar mass 295.42 g/mol

Difemetorex (INN; sold as Cleofil), also known as diphemethoxidine, is a stimulant drug of the piperidine class which was used as an appetite suppressant, but produced intolerable side effects such as insomnia which limited its clinical use.[1][2][3][4][5] It was introduced in France by Ciba-Geigy in 1966 but is now no longer marketed.[6]

See also

References

  1. Isbell H, Chrusciel TS. Dependence Liability of Non-Narcotic Drugs. Bulletin of the World Health Organisation 1970; 43: Supplement.
  2. Stepanek, J; Zolliker, VR (1971). "Circulatory effects of the anorectic Diphemethoxidine compared with the effects of Amphetamine and Aminorex". Archives internationales de pharmacodynamie et de therapie 191 (2): 376–99. PMID 5089225.
  3. Stepanek, J (1972). "Alteration of the acid-base equilibrium by the anorectic diphemethoxidine in comparison with the effect of amphetamine and aminorex". Archives internationales de pharmacodynamie et de therapie 199 (1): 122–38. PMID 5072180.
  4. Hall, Judith A.; Morton, Ian (1999). Concise dictionary of pharmacological agents: properties and synonyms. Kluwer Academic. ISBN 0-7514-0499-3.
  5. "The use of common stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances" (PDF). Retrieved 2010-03-23.
  6. Brudon, Pascale (1983). Médicaments pour tous en l'an 2000?: les multinationales pharmaceutiques suisses face au tiers monde : l'exemple du Mexique. France: Editions d'En bas. p. 207. ISBN 2-8290-0039-0.

This article is issued from Wikipedia - version of the Monday, July 06, 2015. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.